CLRB Cellectar Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1279704 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.2%
TTM EPS YoY70.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-170.0%
ROA-116.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.44x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $11.50M | $26.14M | $27.27M | $18.27M | $17.59M |
| SG&A expense | $11.48M | $25.64M | $11.69M | $10.55M | $6.54M |
| Operating income | -$22.98M | -$51.78M | -$38.96M | -$28.81M | -$24.13M |
| Pretax income | -$21.79M | -$44.52M | -$42.83M | -$31.85M | -$24.12M |
| Income tax | — | $66,000 | -$60,000 | -$60,000 | — |
| Net income | -$21.79M | -$44.58M | -$42.77M | -$31.79M | -$24.12M |
| EBITDA | -$22.77M | -$51.49M | -$38.77M | -$28.67M | -$23.98M |
| EPS (basic) | -8.35 | -36.52 | -3.50 | -4.51 | -4.35 |
| EPS (diluted) | -8.35 | -41.89 | -3.50 | -4.51 | -4.35 |
| Weighted avg. shares (diluted) | 2.61M | 1.24M | 12.22M | 7.06M | 5.55M |
| Balance sheet | |||||
| Cash & equivalents | $13.20M | $23.29M | $9.56M | $19.87M | $35.70M |
| Current assets | $14.04M | $24.25M | $10.45M | $20.53M | $36.57M |
| PP&E, net | $549,405 | $757,121 | $1.09M | $418,641 | $344,491 |
| Total assets | $14.98M | $25.47M | $12.08M | $21.59M | $37.20M |
| Current liabilities | $4.75M | $9.39M | $25.36M | $11.50M | $3.99M |
| Total liabilities | $5.06M | $9.80M | $25.85M | $12.05M | $4.16M |
| Shareholders' equity | $8.54M | $14.29M | -$15.16M | $8.15M | $29.06M |
| Shares outstanding | 4.24M | 1.54M | 20.74M | 9.39M | 6.11M |
| Cash flow statement | |||||
| Operating cash flow | -$23.12M | -$47.58M | -$32.38M | -$25.22M | -$22.57M |
| Capital expenditure | $5,880 | $104,195 | $864,038 | $225,971 | $141,361 |
| Free cash flow | -$23.12M | -$47.69M | -$33.24M | -$25.45M | -$22.71M |
| Investing cash flow | -$5,880 | -$104,195 | -$864,038 | -$225,971 | -$141,361 |
| Financing cash flow | $13.03M | $61.41M | $22.94M | $9.61M | $1.25M |
| Depreciation & amortization | $213,597 | $291,653 | $192,375 | $148,435 | $149,915 |
| Stock-based compensation | $2.26M | $4.27M | $2.41M | $1.45M | $1.12M |
Free plan shows the latest 5 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.